Zyprexa Recent News

January 15, 2009: Eli Lilly to Pay Record $1.42 B in Zyprexa Settlement (FindLaw's Common Law Blog)

October 7, 2008: Zyprexa Makers, 32 States Reach $62M Settlement (FindLaw's Common Law Blog)

January 4, 2007: Eli Lilly Settles Most Zyprexa Claims
Eli Lilly and Company announced that it has entered into settlement agreements to resolve the majority of remaining product liability claims related to the company's antipsychotic drug Zyprexa. Most of these claims assert that before September 2003, Zyprexa package insert information inadequately displayed the risks of hyperglycemia and diabetes. Eli Lilly's settlement includes an estimated 18,000 claims, and is not expected to exceed $500 million in payouts. Approximately 1,200 claims remain. Click here for Eli Lilly's corporate news release.

January 4, 2007: Zyprexa Maker Responds to New York Times Article
Eli Lilly and Company responded to a New York Times article that profiled a patient who allegedly died as a result of Zyprexa use. In its statement, Eli Lilly maintains that it is inaccurate to imply that any single factor -- including medication -- was the cause of the 41 year-old male patient's death. Eli Lilly recommends that patients not discontinue their use of Zyprexa to treat schizophrenia and/or bipolar disorder without first consulting a physician. Click here for Eli Lilly's corporate news release.

December 18, 2006: N.Y. Times Reports Lilly Promoted Unapproved Zyprexa Use
According to the New York Times, Eli Lilly and Company's internal marketing materials reveal that the company encouraged primary care physicians to prescribe Zyprexa (used for schizophrenia and bipolar disorder) to older patients with dementia, an unapproved use of the drug. The report also alleges that Lilly engaged in a campaign to play down the health risks associated with Zyprexa use -- including weight gain and diabetes. In response to the New York Times report, Lilly states that important facts were missing from the article, that its labeling has always sought to warn physicians of the health risks, and that Zyprexa is not a proven cause of diabetes.

  • See Eli Lilly and Company's Response to the New York Times article.

July 24, 2006: Mississippi Sues Eli Lilly Over Sales and Marketing of Zyprexa
The state of Mississippi filed a lawsuit against Eli Lilly and Company, the makers of Zyprexa, alleging improper sales and marketing of the drug. The state alleges that Eli Lilly had a plan to increase sales of Zyprexa while avoiding the expense and delay of obtaining U.S. Food and Drug Administration (FDA) approval for new uses of the drug, allegedly promoting Zyprexa for unapproved uses and failing to warn about the risks associated with Zyprexa use.

July 13, 2006: Mass-Tort Designation Sought for Antipsychotic Drug Lawsuits
In a Middlesex County (New Jersey) court, 235 claims have been filed against the manufacturers of the antipsychotic drugs Risperdal, Seroquel, and Zyprexa. A superior court judge has asked the New Jersey Supreme Court to combine litigation into a single mass tort. The drugs at issue have been allegedly linked to the occurrence of harmful medical conditions, including diabetes.

July 6, 2006: West Virginia Woman Alleges that Zyprexa Caused Diabetes
A West Virginia Woman filed suit against Eli Lilly and Company, the makers of Zyprexa, alleging that the antipsychotic drug caused her diabetes. The lawsuit alleges that Eli Lilly and Company failed to protect potential Zyprexa users by neglecting to warn them of serious health hazards and risks associated with Zyprexa use. The plaintiff alleges that she has suffered diabetes mellitus, physical pain and suffering, mental and emotional anguish and distress, and economic loss.

April, 2006: FDA Alert - Zyprexa Use in Older Patients
The U.S. Food and Drug Administration (FDA) issued an alert announcing its findings that older patients treated with atypical antipsychotics (such as Zyprexa) for dementia had a higher chance for death than patients who did not take the medicine. The FDA further stated that treatment of dementia with atypical antipsychotics is not an approved use, and has asked the manufacturers of these medicines to change their labels to include this important information. Click here to read this alert and other information about Zyprexa.

Next Steps

Contact a qualified product liability attorney to make sure your rights are protected.

Help Me Find a Do-It-Yourself Solution